Treatment for metastatic pancreatic cancer is becoming more personalized, moving away from a “one-size-fits-all” approach. Doctors now consider patient age, side-effect tolerance, and tumor genetics, such as KRAS mutations, when selecting therapy.
NALIRIFOX, approved in 2024, is now a key first-line option. In the NAPOLI 3 trial, it reduced the risk of death by 16% compared to gemcitabine/nab-paclitaxel, and its dose can be adjusted for older or frail patients without losing benefit.
New targeted therapies are emerging, including INCB161734, a drug that inhibits the common KRAS G12D mutation. Early trials show a 37% response rate and 78% disease control, and researchers are testing it in combination with chemotherapy to improve survival. Doctors also consider disease burden, prior treatments, and trial eligibility when choosing therapy, as standard chemotherapy rarely extends survival beyond one year.